Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-21
Target enrollment:
Participant gender:
Summary
This study consists of 2 parts: Dose Escalation Part 1 and Dose Expansion Part 2. The Dose
Escalation Part 1 will evaluate the safety and tolerability of Avelumab in combination with
Lenvatinib and determine the recommended Avelumab and Lenvatinib dose for expansion. Dose
Expansion Part 2 will assess the efficacy of Avelumab in combination with Lenvatinib by
Progression-free Survival in participants with pre-defined primary central nervous system
(CNS) tumors.